Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2CNS 2Thoracic 1Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1Breast 1

Conditions

Neoplasms 4Glioma 3Multiple Myeloma 2Melanoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Nonseminomatous germ cell tumor 1Neurofibroma, Plexiform 1Neurocytoma 1Neuroblastoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Ganglioneuroma 1Ganglioglioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Dexamethasone 16daratumumab 9Bortezomib 9Lenalidomide 6pomalidomide 4carfilzomib 4isatuximab 3trametinib 2selinexor 2dabrafenib 2Thalidomide 2Prednisone 2Melphalan 2ulixertinib 1trastuzumab biosimilar HLX02 1talquetamab 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1montelukast 1melflufen 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1darlin protein, Dictyostelium 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Multiple Myeloma × trametinib × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡